VANTICHLO Trademark

Trademark Overview

On Thursday, October 12, 2017, a trademark application was filed for VANTICHLO with the United States Patent and Trademark Office. The USPTO has given the VANTICHLO trademark a serial number of 87643569. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, May 24, 2021. This trademark is owned by Pfizer Inc.. The VANTICHLO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use
vantichlo

General Information

Serial Number87643569
Word MarkVANTICHLO
Filing DateThursday, October 12, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, May 24, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 20, 2018

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, October 20, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, May 24, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, May 24, 2021ABANDONMENT - NO USE STATEMENT FILED
Saturday, September 19, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, September 18, 2020EXTENSION 5 GRANTED
Thursday, September 10, 2020EXTENSION 5 FILED
Friday, September 18, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, September 10, 2020TEAS EXTENSION RECEIVED
Wednesday, March 18, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 16, 2020EXTENSION 4 GRANTED
Monday, March 16, 2020EXTENSION 4 FILED
Monday, March 16, 2020TEAS EXTENSION RECEIVED
Tuesday, February 4, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, February 4, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, January 30, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, January 30, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, September 12, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 10, 2019EXTENSION 3 GRANTED
Tuesday, September 10, 2019EXTENSION 3 FILED
Tuesday, September 10, 2019TEAS EXTENSION RECEIVED
Tuesday, March 12, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 8, 2019EXTENSION 2 GRANTED
Friday, March 8, 2019EXTENSION 2 FILED
Friday, March 8, 2019TEAS EXTENSION RECEIVED
Wednesday, October 3, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 1, 2018EXTENSION 1 GRANTED
Monday, October 1, 2018EXTENSION 1 FILED
Monday, October 1, 2018TEAS EXTENSION RECEIVED
Tuesday, April 17, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 20, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 20, 2018PUBLISHED FOR OPPOSITION
Wednesday, January 31, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, January 8, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 3, 2018ASSIGNED TO EXAMINER
Friday, October 20, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, October 16, 2017NEW APPLICATION ENTERED IN TRAM

Related Keywords

vantichlo preparations disorders pharmaceutical dysfunction treatment liver erectile blood viral urological